

Pathways for Approval for Post-PMTA Product Modifications

October 25, 2019

Matt Holman, Director, Office of Science, CTP, FDA

Patricia Miller, Senior Director, Premarket Tobacco Applications, Altria Client Services LLC

Moderated by **Elizabeth Oestreich,** Vice President, Regulatory Compliance, Greenleaf Health



AGENDA:

- Current state of modifications
- Why are we discussing this topic?
- Presentations
- Discussion on FDA's proposed rule and implementation
- Questions



New Tobacco Product

Section 910(a)(1) of the FD&C Act defines a new tobacco product as:

- Any tobacco product (including those products in test markets) that was not commercially marketed in the US as of February 15, 2007 or
- Any modification (including a change in design, any component, any part, or any constituent, including a smoke constituent, or in the content, delivery or form of nicotine, or any other additive or ingredient) of a tobacco product where the modified product was commercially marketed after February 15, 2007.





Premarket Tobacco Product Applications and Recordkeeping Requirements Proposed Rule – September 25, 2019

Comment period closes on November 25, 2019

AUTHENTICATED & COVERNMENT INFORMATION GPO

Federal Register/Vol. 84, No. 186/Wednesday, September 25, 2019/Proposed Rules 50566

DEPARTMENT OF HEALTH AND HUMAN SERVICES	Electronic Submissions Submit electronic comments in the	with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The
Food and Drug Administration	following way: • Federal eRulemaking Portal:	Agency will review this copy, including the claimed confidential information, in
21 CFR Parts 1100, 1107, and 1114	https://www.regulations.gov. Follow the instructions for submitting comments.	its consideration of comments. The second copy, which will have the
[Docket No. FDA-2019-N-2854]	Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to	claimed confidential information redacted/blacked out, will be available
RIN 0910-AH44	the docket unchanged. Because your	for public viewing and posted on https://www.regulations.gov. Submit
Premarket Tobacco Product Applications and Recordkeeping Requirements	comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a	both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you
AGENCY: Food and Drug Administration, HHS.	third party may not wish to be posted, such as medical information, your or	
ACTION: Proposed rule.	anyone else's Social Security number, or confidential business information, such	must identify this information as "confidential." Any information marked
SUMMARY: The Food and Drug Administration (FDA) is issuing a proposed rule that would set forth requirements for premarket tobacco product applications (PMTAs) and would require manufacturers to maintain records establishing that their tobacco products are legally marketed.	 as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. If you want to submit a comment with confidential information that you do not wigh to be medo available to the 	as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. Fo more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.fda.gov. regulatory-information/dockets-

management. - 21 .



do not wish to be made available to the The proposed rule would help to ensure public submit the comment as a

FDA'S CENTER FOR TOBACCO PRODUCTS: PATHWAY FOR APPROVAL OF POST-PMTA PRODUCT MODIFICATIONS

Matthew R. Holman, Ph.D. Director Office of Science Center for Tobacco Products

Disclaimer: This is not a formal dissemination of information by FDA and does not represent Agency position or policy.



CENTER FOR TOBACCO PRODUCTS

October 25, 2019 | Food and Drug Law Institute (FDLI)

WHAT DOES THE PMTA RULE PROPOSE?

- Basic content and format
- General review procedures
 - From application receipt to order issuance
 - Communications from FDA
- Recordkeeping
 - Establishing that tobacco product is legally marketed
- Inspections

WHAT DOES THE PMTA RULE PROPOSE?

FDA

- Electronic submission requirement
- Refuse To Accept (RTA) criteria
 - o Must meet minimal content & format requirements
- Refuse To File (RTF) criteria
 - Must include substantive information on product health risks, comparative tobacco product information, abuse liability, actual use, likelihood of changes in use behavior by current users and non-users, & consumer perceptions

WHAT ARE SOME BENEFITS OF THE PMTA RULE?

- Helps ensure that PMTAs contain sufficient information for FDA to determine whether to issue a marketing order
- Facilitates submission of streamlined PMTAs
 - Supplemental PMTA & Resubmission
 - Reduces burden on FDA & applicants
- Creates postmarket reporting requirements
 - Allows FDA & applicants to assess public health impact of product marketing

WHAT ARE SOME BENEFITS OF THE PMTA RULE?

- Describes how to use scientific literature to bridge to new product
 - Data on products other than new product can be informative
- Clarifies the 180-day review period
 - Describes when FDA may pause or extend the review clock



Proposed § 1114.15

"Applicants that *have received a marketing order* for a tobacco product may...submit a supplemental PMTA to seek marketing authorization for modifications to such product... Supplemental PMTAs must include *new information concerning modifications* that create the new tobacco product but allow the applicant to satisfy the remaining application requirements *by crossreferencing applicable content from the previously submitted PMTA* for the original tobacco product. Applicants may submit supplemental PMTAs *only for modifications that require the submission of limited new information.*"



Potentially Appropriate for Supplemental PMTA

- Modification to meet product standard (if specified by FDA)
- Changes in connection type/thread size
- Minor software changes not affecting device functionality
- Minor changes in e-liquid volume, viscosity or boiling temperature
- Minor changes in draw resistance
- Minor changes in air flow rate
- Changes to coil configuration if number of coils, coil gauge, material, and overall coil
 resistance remain unchanged
- Changes to amount of wicking material
- Minor changes in wick ignition temperature



Likely Not Appropriate for Supplemental PMTA

- Modification that might increase risk of harm to individual health from the product
- Modifications that may alter tobacco product use behavior and initiation, such as modifications that have strong youth appeal
- Design modifications that change the category or subcategory of the product (e.g., modifying a closed e-cigarette to be an open e-cigarette)



Not Allowed for Supplemental PMTA

- Marketing order for the original tobacco product has been
 - o Withdrawn
 - Temporarily suspended
 - o Is subject of temporary suspension or withdrawal proceedings by FDA
- FDA may authorize exception to the situations above
 - Applicant must request exception
 - If reason for the temporary suspension or withdrawal is unrelated to sufficiency or reliability of information in the PMTA

WHY IS CTP PROPOSING SUPPLMENTAL PMTA?

- Reduces review burden on CTP
 - o Not reassessing information that has already been evaluated
- Maintains rigorous standard for issuing marketing orders
 - Doesn't change legal or scientific requirements for order
- Consistent with other FDA Centers
 Ex: NDA supplements

WHY IS CTP PROPOSING SUPPLMENTAL PMTA?

- Allows for faster marketplace changes that are positive for public health
 - Ex: Compliance with product standards
 - Ex: Safety improvements
- Allows applicant to avoid resubmitting information already provided to CTP
 - Doesn't slow down speed of positive marketplace changes
 - Provides information to CTP in most useful way

CONCLUSION



- Proposed rule provides public with CTP's thinking on PMTAs
 - Read it carefully
 - o Preamble outlines why we are proposing what is captured in codified
- Supplemental PMTAs are important creation
 - Allows focusing of resources are most salient information
- All stakeholders should provide comments to the proposed rule by November 25
 - CTP evaluates all comments in preparing the final rule



Pathways for Approval of Post-PMTA Modifications

Patricia M. Miller, Esq. Senior Director, Regulatory Affairs Altria Client Services



Importance of Modifications – Technology Changes Rapidly



2009

<u>2019</u>



Potential Drivers of Product Modifications

Consumer Complaints

Product Safety Concerns

Product Misuse

Technology to Prevent Youth Access

Supplier Issues

Manufacturing Efficiencies

Modifications Can Create a "New" Product

<u>New Tobacco Product</u> means...any modification (including a change in design, any component, any part, or any constituent, including a smoke constituent, or in the content, delivery or form of nicotine, or any other additive or ingredient) of a tobacco product where the modified product was commercially marketed in the United States after February 15, 2007.



Current Product Change Pathways

Substantial Equivalence:

- Requires predicate product
- Same characteristics, or different characteristics but product does not raise different questions of public health

SE Exemption:

- Legally marketed product
- Modified by adding or deleting a tobacco additive, or increasing or decreasing the quantity of an existing tobacco additive
- Minor modification

Current Product Change Pathways

PMTA Marketing Orders

- <u>Limited</u> post-authorization changes implied by periodic reporting:
 - Changes to <u>manufacturing process</u>, facilities, or <u>controls</u> (that do not result in product modification)
 - Final printed <u>labeling</u>, with description of all changes

FDA NEWS RELEASE	-
FDA permits sale of IQOS Tobacco Heating System through premarket tobacco product application pathway	
Agency places stringent marketing restrictions on heated tobacco products aimed at preventing youth access and exposure to the new products	
For Immediate Release:	
April 30, 2019	

Proposed Supplemental PMTA – Overview

- Alternative PMTA format to reduce the burden associated with submission and review
- "Submission of limited information or revisions to the PMTA to make it apply to the modified tobacco product."¹
- Can be used to comply with a product standard under § 907
- Format/content 1) New content sections; 2) Crossreferenced content sections
- Certification of no other modifications


1. Premarket Tobacco Product Applications and Recordkeeping Requirements Proposed Rule, September 2019

Applicant	SUBMISSION	REFORMATION A. A. FDA Receipt Date	
Product Manufacture	Philp Morris Products 5	A.	Lor or No.
FORTHER OTH	(or an out	FDA Receipt Data	0919200
Primary STN(x)		Mariboro Heatsticks ¹ Mariboro Srepoth Mari	thoi Heatsticks ¹
	PM0000426 PM0000479	Mariboro Sreacth Mar Mariboro Fresh Menth KOS System Holder an Primary STN(s)	ol Heatsticks ¹
Cross referenced Submission(s)	Cross-referenced STN	Primary STN(s)	
Submission(s)	MR0000059 MR0000060	APPLIES TO PM000042 PM0000479	4-P%/0000426,
	MR0000061 MR0000113		
	MF000013 MF0000013 MF0000243	-	
	MF0000243 MF0000264	-	
¹ May be odd individually	er as co packaged product.		
PMTA Covershe	at: Technical Proje	ct Load Review /T	13, Fuor & Drug Mar 1983 Aust Teachan Shar Sanga Shar Sanga Teu J
PASTA Coursethe	at: Technical Proje	ct Load Review /T	(PIL)
PASTA Coursethe	at: Technical Proje	ct Load Review /T	(PIL)
PMTA Covershe Applicant Product Manufacture Soleniusian Date	SUBMISSION SUBMISSION Philp Morra Products 5 Philp Morras Products 5 05-25-2017	ct Load Review /T	(PIL)
PMTA Covershe Applicant Product Manufacture Soleniusian Date	SUBMISSION SUBMISSION Philp Morra Products 5 Philp Morras Products 5 05-25-2017	ct Lead Review (T I DEFORMATION A.	(05-15-20
PMTA Covershe Applicant Product Manufacture Soleniusian Date	SUBMISSION SUBMISSION Philp Morra Products 5 Philp Morras Products 5 05-25-2017	ct Lead Review (T I DEFORMATION A.	(05-15-20
PMTA Covershe Applicant Product Nanufacture Sobrelasian Date	SUBMISSION Filip Morris Products 5 05-35-2017 PM0000424 PM0000426 PM0000425 PM00000425 PM0000425 PM0000425 PM0000000	ct Lead Review (T I DEFORMATION A.	(05-15-20
PMTA Covershe Applicant Product Nanufacture Sobrelasian Date	et: Technical Proje summission Philip Morris Products 5 05-35-2017 Philopotexts 05-35-2017 Philopotexts Philo	ct Lead Review (T ex-CARMATION A FOA Receipt Data Mariboro Hestatics) Mariboro seatch Me Mariboro Fresh Meeth Mariboro Fresh Meeth North System Roller Phimery ST(s)	(DL) (05-15-2) athol Heatsticks ¹ al Heatsticks ¹ al Obarger ²
PMTA Covershe Applicant Product Nanufacture Sobrelasian Date	Et: Technical Proje SUBMISSON Philp Morris Products 5 65-55-2017 PM0000425 PM0000426 PM000426 PM0000426 PM0000426 PM00040 PM00040040 PM0000000000	ct Lead Review (T I DEFORMATION A.	(DL) (05-15-2) athol Heatsticks ¹ al Heatsticks ¹ al Obarger ²
PMTA Covershe Applicant Product Manufacture Soleniusian Date	Et: Technical Proje SUBMISSON Philp Morris Products 5 65-55-2017 PM0000425 PM0000426 PM000426 PM0000426 PM0000426 PM00040 PM00040040 PM0000000000	ct Lead Review (T ex-CARMATION A FOA Receipt Data Mariboro Hestatics) Mariboro seatch Me Mariboro Fresh Meeth Mariboro Fresh Meeth North System Roller Phimery ST(s)	(DL) (05-15-2) athol Heatsticks ¹ al Heatsticks ¹ al Obarger ²
PMTA Covershe Applicant Product Nanufacture Sobrelasian Date	et: Technical Proje summission Philip Morris Products 5 05-35-2017 Philopotexts 05-35-2017 Philopotexts Philo	ct Lead Review (T ex-CARMATION A FOA Receipt Data Mariboro Hestatics) Mariboro seatch Me Mariboro Fresh Meeth Mariboro Fresh Meeth North System Roller Phimery ST(s)	(PL) (05-15-30 athor Heatstocks ¹ and Heatstocks ² and Charger ²

Proposed Supplemental PMTA Assessment

Proposed Supplemental PMTA Strengths

- Creation of streamlined pathway
- Builds from § 910 framework
- Clear guidance on proposed content
- Helpful examples of modifications for ENDS, at least



Proposed Supplemental PMTA Assessment

Ambiguity of Supplemental Pathway Access

"...only for a modification or modifications that require the submission of <u>limited</u> <u>information</u>..."

"applicant would not be able to submit...to the extent that reviewing a supplemental application would be...<u>confusing, cumbersome, or otherwise inefficient</u>..."

"Changes that require <u>multiple</u>, <u>sweeping</u>, <u>or difficult-to-trace</u> changes...would be more efficient to review in full text format..."

Premarket Tobacco Product Applications and Recordkeeping Requirements Proposed Rule, September 2019 (Emphasis added)


Proposed Supplemental PMTA Assessment

Length of Review Period

- Length of supplemental PMTA review process not specified in Proposed Rule or preamble
- PMTA = 180-day review period?
- But "FDA estimates further that a supplemental PMTA will take 25 percent of the time it takes to do an original submission..."¹

1. Premarket Tobacco Product Applications and Recordkeeping Requirements Proposed Rule, September 2019

PMTA Timeline



Possible Review for Minor Modifications

